TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07734649: A Phase 1/2, Randomized, Controlled, Observer-Blind Study in Adults 60 Years of Age and Older to Evaluate the Immunogenicity and Safety of Different Dose Levels of a Bivalent Vaccine Candidate Against Respiratory Syncyti

Sponsor: Sanofi · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 2400 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$9,384,000

Rescue Site Savings

+$6,187,575

Unlock Full NCT07734649 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07734649 Rescue Dossier →